Posts Tagged EMR
Women’s Health in a Digital World
At www.healthtechnologyforum.com annual conference in San Francisco, a group of eminent panel members, discussed opportunities and challenges in women’s health. Not only healthcare in general is undergoing a major transformation, but the panelists highlighted how the world of women’s health might also transform in the coming decade, as technology is increasingly used to address and bridge the gap that currently exists in women’s health and wellness.
Christina Resasco, Founder of Mobilize for Cure and Leukemia & Lymphoma Society’s 2013 “Woman of the Year” award winner, moderated the panel, and asked insightful questions. Below are some highlights.
Robin Farmanfarmaian is a serial entrepreneur. Hear early diagnosis and battling an auto immune disease, later gave her the inspiration and passion for health and wellness. Farmanfarmaian has been a driving force behindSingularityUniversity’s highly successful FutureMed conferences. Farmanfarmaian said, the practice of medicine will be completely disrupted in 2-5 years and will involve POC devices that will enable consumer to be a key decision maker; devices that will help in early diagnoses of several diseases taking the doctor out of it.
Fiona Ma http://bit.ly/1pK4k5R, incumbent democratic candidate for State Board of Equalization, a reputed politician, and a former member of the San Francisco Board of Supervisors, California State Assembly. She has long a standing interest in health and wellness and is a tireless campaigner and spokesperson for “San Francisco Hepatitis B Free” campaign. Ma herself has battled Hepatitis virus. According to Ma, technologies that help the efficient and seamless transition to EMR or electronic medical records, will be very important. She also talked about how the government needs to find creative ways to work with the private sector, and not work in functional silos. Her advice to women seeking to compete in the men’s world was to be proactive in taking on greater responsibilities and self selecting when required, rather than waiting for others to appoint them.
Panelist Danielle Posa was diagnosed with stage 3 Non-Hodgkins Lymphoma http://bit.ly/QIKSHn, at the age of 5 and learned early about the value and limitations of human life. She campaigns and consults on health and wellness, and helps in fund raising efforts for Leukemia and Lymphoma societies. Posa has been interviewed by Deepak Chopra on his show “One World” and has also spoken alongside him. According to Posa, we need to integrate both the science and the art in implementing healthcare in the workplace. She seeks to connect the public and the private sector leaders and help them broaden their focus from traditional metrics like GDP to more wholistic measures that reflect the quality of life.
Anne DeGheest (http://bit.ly/176Ij4j ) founded Healthtech Capital and MedStars Venture Partners several years ago, with a mission to save lives, through utilization of technology. She believes, we need to think outside the box to influence positive change in consumer behaviors, in order to disrupt healthcare. She firmly believes that data for the sake of data does not do anything; instead technology focus will have to be on solving pain points. She said entrepreneurs often neglect the market and focus on building prototypes or products. She advised that instead the entrepreneurs focus on understanding the market and the value proposition they are offering, in to solve the pain points. She said historically healthcare has been sold to men, but in many households, the “chief medical officer” at home, are moms. One of the disruptions will occur on account of the wider role that pharmacy chains will likely play in healthcare, in future. Most of the Americans live within 3 mile radius of pharmacy chains and these chains will step in to provide basic care.
Vanessa Mason serves as Senior Manager with eHealth and ZeroDivide. She manages the project portfolio, contributing to design, development, and adoption of products and services that promote health equity. With a strong focus on healthcare disparity and how that negatively impacts women, Mason has sought to bridge the gap through efficient use of technology. By some estimates, in certain geographical areas in the US, about 4 in 10 women, do not receive healthcare. Rates of women without health insurance have been higher among African American women. Some recent projects “text for wellness” and “mobilize”, focused on cardivascular health prevention for African-American women. This was a great example of efficient use of technology that did not add to the costs, but effectively connected people to keep them informed and focused on meeting their wellness goals. Often these women are pursuing career opportunities while single handedly taking care of families and have to navigate multiple worlds. Technology can only help if it is easily accessible and affordable. She advised entrepreneurs that they focus on enhancing quality of life of the 80% of population towards the bottom of the pyramid, where there are many gaps that also represent huge opportunities.
Evidence Based Medicine – Aligning Labs, Clinicians & Payers for Better Diagnostic Decisions
Posted by Darshana V. Nadkarni, Ph.D. in Biotech - Medical Device - Life Science - Healthcare on August 19, 2013
Mark Zubiller, VP of Decision Management at McKesson, talked about value based medicine by driving better diagnostic decisions through collaborative model, aligning labs, clinicians, and payers, at www.bio2devicegroup.org event.
Molecular diagnostic tests identify molecular and genetic markers for an individual patients that help determine potential benefit from a specific, targeted therapy. Molecular diagnostic tests have become a big buzz word but the area is fraught with challenges. There isn’t a lot of clinical evidence that support many of these tests which are often based on extreme of a diagnostic marker, so there needs to be more data churning to demonstrate clinical utility of the data. Second, there is limited point of service information. Only 20% of molecular diagnostic tests on the market have evidence based guidelines today, although 75% of the providers believe that patients in their practice would benefit from having a genetic test. As new tests continue to emerge, physicians cannot keep up with information about newer tests and their efficacy. Third, many of the tests are unidentifiable. There is no catalogue for identifying the tests, coding information is nonspecific, and payers do not have consistent way to code and pay for these. Payers require clinical utility for coverage. This often leads to denials and reapplications and generates a lot of frustration for everyone involved. Finally, this results in increased paperwork and payer scrutiny.
Currently, market does not have a way to address this challenge and it is stuck between innovation and execution. There is a great deal of system fatigue, on account of increasing administrative burden, reform compliance etc. but while innovation is greatly needed, it would bring reimbursement shifts, additional administrative challenges, and a need for collaboration among the stakeholders. Payers, labs, and providers essentially share the same challenge of ensuring that patients get the right care at the right cost, without increased administrative burden. Existing traditional payer programs operate in silos and do not have a way of engaging providers. They require expensive manual resources and are struggling with administration, transparency, and consistency. Lack of collaboration exerts a huge financial burden on both the providers and the payers. Providers spend $31 billion annually and payers spend $74 billion annually that could be saved, with greater collaboration.
Explaining the McKesson value based care model, Zubiller said, it means “balancing value-based reimbursement with value-based care delivery at the point of care. As the patient care progresses from care selection to care plan to network selection to reimbursement, point of care decisions happen at each stage that impact cost, care, and value. Earlier and better decisions would greatly reduce cost, improve care, and provide better value, said Zubiller. A value based diagnostics strategy has to be based upon collaboration between labs, payers, and providers for identification of tests, for determination of cataloging and coverage, for consistent evidence based payer and lab policies, for decision support rules integrated into EMR, and for sophisticated performance data analytics for payment.
The talk was followed by Q&A. Explaining the strategy, Zubiller said, McKesson is a business that works with health care stakeholders in every setting and is therefore taking the lead to chart the course towards a stronger more sustainable future, for the entire industry. McKesson is a leading provider of enterprise information technology solutions, including software, services, automation, and consulting to hospitals, physician offices, imaging centers, home health care agencies, and payers. With strategic use of IT solutions to bring greater connectivity in the healthcare ecosystem and by leveraging its credibility to bring the stakeholders to the table for collaborative dialog, McKesson hopes to lead implementation of value based care model that would be a win-win solution for payers, providers, labs and for patients.